Revolutionary IIT Jodhpur Discovery Unveils Human Protein Against Bacterial Biofilms
Researchers at the Indian Institute of Technology Jodhpur (IIT Jodhpur) have made a significant advance in combating antimicrobial resistance with their recent publication in the prestigious Proceedings of the National Academy of Sciences (PNAS). Led by Dr. Neha Jain, Associate Professor in the Department of Bioscience and Bioengineering, the team identified β2-microglobulin (β2m)—a naturally occurring human protein—as a potent inhibitor of bacterial biofilms formed by Escherichia coli (E. coli). This breakthrough highlights IIT Jodhpur's growing stature in biomedical research, positioning it as a key player in India's efforts to address global health challenges.
Biofilms are complex communities of bacteria encased in a self-produced matrix, rendering them up to 1,000 times more resistant to antibiotics than free-floating bacteria. These structures contribute to 65-80% of chronic infections worldwide, including those on medical devices like catheters and implants. In India, where antimicrobial resistance (AMR) claims nearly one million lives annually, such innovations are crucial for developing sustainable therapies.
Dr. Jain's Functional Amyloid Biology (FAB) Lab focuses on the interplay between bacterial and human amyloids, exploring their roles in infections and neurodegeneration. This PNAS study, published on February 18, 2026, in Volume 123, Issue 8, demonstrates how β2m selectively disrupts curli assembly—a critical step in biofilm formation—without killing the bacteria, thus minimizing resistance development.
The Science Behind Bacterial Biofilms and Their Global Impact
Bacterial biofilms represent a survival strategy honed by evolution. In hostile environments, bacteria aggregate, producing an extracellular matrix of amyloids like curli, polysaccharides, and extracellular DNA (eDNA). Curli, functional amyloid fibers in E. coli, act as scaffolds, enabling adhesion to surfaces and protection from host defenses and drugs.
Globally, biofilms are implicated in persistent infections such as urinary tract infections, wound infections, and device-related sepsis. In India, high antibiotic overuse exacerbates AMR, with resistance rates exceeding 70% for many pathogens. Chronic wounds alone affect millions, often failing standard treatments due to biofilm persistence.
The IIT Jodhpur team's work shifts the paradigm from bactericidal agents to matrix disruptors. By targeting curli early assembly, β2m prevents the biofilm shield from forming, exposing bacteria to natural immune clearance or milder antibiotics.
Unraveling the Mechanism: How β2-Microglobulin Targets Curli
β2-Microglobulin, a component of major histocompatibility complex (MHC) class I molecules on cell surfaces, circulates freely in human serum. The study employed a multifaceted approach: biophysical assays showed β2m binds curli monomers, halting polymerization into amyloid fibrils; biochemical tests confirmed dose-dependent biofilm reduction; computational modeling revealed specific interactions at curli's nucleation sites.
- Biophysical: Thioflavin T fluorescence assays demonstrated inhibited amyloid formation.
- Microscopic: Scanning electron microscopy (SEM) and confocal imaging visualized disrupted biofilm architecture.
- Computational: Molecular dynamics simulations pinpointed β2m-curli binding interfaces.
This selective inhibition spares planktonic bacteria, avoiding selective pressure for resistance—a common pitfall of antibiotics.
Research Methodology: A Multidisciplinary Effort at IIT Jodhpur
The study integrated expertise from biophysics, microbiology, and structural biology. Key team members included PhD scholars Harshita Agarwal, Himanshu Ben, Anwesha Chaini, and others, supported by facilities like IIT Jodhpur's Central Research Facility (CRF) and Centre of Excellence-AyurTech.
In vitro experiments used E. coli strains engineered with curli plasmids. In vivo validation involved a Wistar rat skin wound model, where β2m-treated wounds healed faster, with reduced bacterial load and inflammation markers. Funding from IIT Jodhpur SEED grants, ICMR, CSIR, and EMBO underscored institutional support for high-impact research.
This rigorous pipeline exemplifies how newer IITs like Jodhpur foster interdisciplinary innovation, attracting talent for research jobs in higher education.
In Vivo Validation: Accelerating Wound Healing Against Biofilm Infections
Beyond lab dishes, the rat model mimicked chronic wounds: E. coli inoculation delayed healing, but topical β2m restored timelines comparable to uninfected controls. Histology showed diminished biofilm matrix and enhanced re-epithelialization.
This translates to real-world potential for diabetic foot ulcers or implant infections, prevalent in India amid rising diabetes rates (over 100 million cases).
Read the full PNAS studyImplications for Combating Antimicrobial Resistance in India
AMR costs India billions in healthcare, with biofilms fueling 80% chronic cases. β2m-inspired therapies could synergize with antibiotics, restoring efficacy. Unlike broad-spectrum drugs, curli inhibitors target a conserved process across pathogens.
- Reduces resistance evolution by sparing viable bacteria.
- Harness host molecules for biocompatibility.
- Potential nasal sprays for respiratory biofilms or coatings for implants.
For aspiring researchers, this opens avenues in postdoc opportunities at institutions like IIT Jodhpur.
IIT Jodhpur's Ascendancy in Indian Higher Education Research
Established in 2008, IIT Jodhpur ranks #27 in NIRF Engineering 2025 and excels in research output. Dr. Jain, an EMBO Global Investigator and INSA Young Associate, leads with prior PNAS work on transthyretin (another amyloid inhibitor). The institute's facilities enable such feats, drawing funding and collaborations.
In Rajasthan's academic landscape, IIT Jodhpur inspires students via programs like higher ed jobs in India.
Future Outlook: From Lab to Clinic and Beyond
Next steps include optimizing β2m variants for stability and testing against multi-species biofilms. Partnerships with pharma could yield curli-inhibitor drugs. In higher ed, this boosts India's R&D, aligning with NEP 2020's research emphasis.
Dr. Jain notes: "This approach opens possibilities for therapies inspired by the body’s own tools."
Dr. Neha Jain's IIT Jodhpur profileStakeholder Perspectives and Broader Higher Ed Impact
Government bodies like PIB hail it as India's contribution to AMR solutions. Peers recognize curli targeting's promise, building on prior inhibitors like transthyretin.
For students, this exemplifies translational research careers; check career advice for paths in biosciences.
Photo by Jarnail Singh on Unsplash
Conclusion: Pioneering a New Era in Infection Control
The IIT Jodhpur PNAS breakthrough on β2-microglobulin blocking bacterial biofilms marks a milestone in host-derived therapies. As AMR escalates, such innovations from Indian academia offer hope. Explore opportunities at RateMyProfessor, higher-ed-jobs, career advice, university jobs, or post a job to join this vanguard.